Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, NewAmsterdam Pharma Company NV’s stock clocked out at $23.39, down -2.46% from its previous closing price of $23.98. In other words, the price has decreased by -$2.46 from its previous closing price. On the day, 0.78 million shares were traded. NAMS stock price reached its highest trading level at $24.06 during the session, while it also had its lowest trading level at $22.89.
Ratios:
To gain a deeper understanding of NAMS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.98 and its Current Ratio is at 19.98. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 17, 2025, initiated with a Neutral rating and assigned the stock a target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.Stifel initiated its Buy rating on June 10, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 16 ’25 when Kling Douglas F sold 51,043 shares for $21.10 per share. The transaction valued at 1,077,007 led to the insider holds 44,000 shares of the business.
Kling Douglas F sold 47,569 shares of NAMS for $1,019,648 on Jul 15 ’25. The Chief Operating Officer now owns 44,000 shares after completing the transaction at $21.44 per share. On Jul 14 ’25, another insider, NAP PoolCo B.V., who serves as the Affiliate of the company, bought 1,433,193 shares for $21.56 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2626018560 and an Enterprise Value of 1817923072. For the stock, the TTM Price-to-Sale (P/S) ratio is 55.71 while its Price-to-Book (P/B) ratio in mrq is 3.38. Its current Enterprise Value per Revenue stands at 38.564 whereas that against EBITDA is -9.589.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.01, which has changed by 0.24019086 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 18.65%, while the 200-Day Moving Average is calculated to be 13.15%.
Shares Statistics:
It appears that NAMS traded 836.80K shares on average per day over the past three months and 786910 shares per day over the past ten days. A total of 112.17M shares are outstanding, with a floating share count of 62.20M. Insiders hold about 44.60% of the company’s shares, while institutions hold 57.52% stake in the company. Shares short for NAMS as of 1751241600 were 6875637 with a Short Ratio of 8.22, compared to 1748563200 on 6558666. Therefore, it implies a Short% of Shares Outstanding of 6875637 and a Short% of Float of 7.31.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
